Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBITDA (2016 - 2025)

Historic EBITDA for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$170.9 million.

  • Ultragenyx Pharmaceutical's EBITDA fell 2947.49% to -$170.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$544.0 million, marking a year-over-year decrease of 154.01%. This contributed to the annual value of -$536.0 million for FY2024, which is 583.88% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's EBITDA is -$170.9 million, which was down 2947.49% from -$107.9 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EBITDA peaked at -$82.8 million during Q2 2021, and registered a low of -$225.1 million during Q3 2022.
  • Its 5-year average for EBITDA is -$134.6 million, with a median of -$136.6 million in 2022.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's EBITDA tumbled by 15055.22% in 2022, and later surged by 3553.14% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's EBITDA stood at -$102.6 million in 2021, then plummeted by 41.99% to -$145.6 million in 2022, then grew by 16.19% to -$122.0 million in 2023, then fell by 0.19% to -$122.3 million in 2024, then crashed by 39.76% to -$170.9 million in 2025.
  • Its EBITDA stands at -$170.9 million for Q3 2025, versus -$107.9 million for Q2 2025 and -$142.9 million for Q1 2025.